CDX 101
Alternative Names: CDX-101Latest Information Update: 14 Oct 2021
At a glance
- Originator Cardax Pharmaceuticals
- Class Anti-inflammatories; Antihyperlipidaemics; Cardiovascular therapies
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Dyslipidaemias
- No development reported Hypertriglyceridaemia
Most Recent Events
- 01 Oct 2021 CDX 101 is available for licensing as of 01 Oct 2021. https://cardaxpharma.com/cdx-101/ (Cardax Pharmaceuticals pipeline, October 2021)
- 01 Oct 2021 Preclinical trials in Cardiovascular disorders in USA (PO) (Cardax Pharmaceuticals pipeline, October 2021)
- 01 Oct 2021 Preclinical trials in Dyslipidaemias in USA (PO) (Cardax Pharmaceuticals pipeline, October 2021)